Alveolar Cleft Graft Using Khoury Shell Technique (Alveolar cleft)

September 18, 2026 updated by: Khalid Karkar, Ministry of Health, Kuwait

Evaluation of Alveolar Cleft Grafting Using Khoury Shell Technique

Iliac cancellous bone is considered the gold standard graft material for secondary ABG, which was applied as a block or granules, and difficult to be stabilized in the recipient site causing dislodgment of the graft which in turn leads to resorption and/or continuity between nasal and oral cavities. On the other hand, the cortico-cancellous block graft produces more mechanical strength and stability, but the cortical part is less vascular, and so establishment of nutritional supply to cortical cells is a slow process. Therefore, this graft generally resorbs and is replaced by invasion of bone cells originating from the recipient site. Khoury F. and Khoury CH. made a variation by splitting the solid cortical bone into two thinner shells, so more vascular chips can be packed and take the advantage of more and early revascularization of cancellous bone plus the advantage of cortical bone in terms of mechanical stability and restoring the labial plate. In this study, we evaluate the regenerated bone following alveolar cleft grafting using Khoury shell technique.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sabah Alnasser
      • Al Farwaniyah, Sabah Alnasser, Kuwait, 00000
        • Alfarwaniya Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 14 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • were patients within the age range of 7-14 years and with a unilateral or bilateral alveolar cleft in anterior maxilla.

Exclusion Criteria:

  • were history of intravenous and/or oral bisphosphonate use, irradiation of the head and neck region, infection, immunocompromised and medically compromised (such as Diabetics) patients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: inclusive arm

This a single arm evaluative study in which an alveolar cleft grafting was done using Khoury shell technique from anterior iliac crest

The cortical shell was secured in position labially by means of two micro-screws (1.5mm diameter), creating labial plate for the defect site. Sharp edges of the cortical shell were smoothened. A collagen membrane was applied beneath the palatal mucoperiosteum to cover and protect the graft from the dislodgment palatally and the growth of soft tissue. The created gap between the cortical shell and the collagen membrane was filled by the cancellous bone granules and the whole graft covered by the collagen membrane

Other Names:
  • Alveolar cleft grafting using Khoury shell technique

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
CBCT
Time Frame: 6 months
6 months
Continuity of labial plate and maxillary arch
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2023

Primary Completion (Actual)

March 1, 2026

Study Completion (Actual)

March 3, 2026

Study Registration Dates

First Submitted

September 18, 2026

First Submitted That Met QC Criteria

September 18, 2026

First Posted (Actual)

September 24, 2026

Study Record Updates

Last Update Posted (Actual)

September 24, 2026

Last Update Submitted That Met QC Criteria

September 18, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KW26/OMFS10018

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.